-

Anika to Participate in 2020 UBS Virtual Global Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company, today announced that Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will present at the 2020 UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8:20 a.m. ET.

A live audio webcast of the session may be accessed via the “Investor Relations” section of Anika’s website at www.anikatherapeutics.com. An audio archive of the session will also be available on the website.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated joint preservation and regenerative therapies company based in Bedford, Massachusetts. Anika is committed to delivering therapies to improve the lives of patients across a continuum of care from osteoarthritis pain management to joint preservation and restoration. The Company has close to three decades of global expertise commercializing more than 20 products. For more information about Anika, please visit www.anikatherapeutics.com.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
investorrelations@anikatherapeutics.com

For Media Inquiries:
W2O Group
Jeremy Berrington, 312-241-1995
jberrington@w2ogroup.com

Industry:

Anika Therapeutics, Inc.

NASDAQ:ANIK
Release Versions
English

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
investorrelations@anikatherapeutics.com

For Media Inquiries:
W2O Group
Jeremy Berrington, 312-241-1995
jberrington@w2ogroup.com

More News From Anika Therapeutics, Inc.

Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced that Cheryl R. Blanchard, Ph.D., has been named President and Chief Executive Officer, effective April 26,2020. Dr. Blanchard has served as interim Chief Executive Officer of Anika since February 2020 and as a member of the Company’s Board of Director...

Anika to Issue First Quarter 2020 Financial Results and Business Highlights on Thursday, May 7

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first quarter 2020 financial results after the close of the market on Thursday, May 7, 2020 and hold its investor conference call on the same day, Thursday, May 7, 2020, at 5:00 p.m. ET to discuss its financial results, business highlights, and outlook. The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A...

Anika Appoints David Colleran as General Counsel

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform, today announced the appointment of David Colleran to the newly created position of Executive Vice President, General Counsel and Corporate Secretary. In this new role, Mr. Colleran will lead the Company’s global legal organization, including corporate governance and...
Back to Newsroom